Mogenry (sonpiretigene isteparvovec, MCO-010) for Retinitis pigmentosa with severe vision loss
One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Retinitis Pigmentosa. Unsubscribe anytime.
The FDA is expected to decide on Mogenry for Retinitis pigmentosa with severe vision loss in an undisclosed window, under a BLA from Nanoscope Therapeutics.
What is being decided
Nanoscope Therapeutics has a BLA under FDA review for Mogenry (sonpiretigene isteparvovec, MCO-010) in Retinitis pigmentosa with severe vision loss. One-time in-office injection that makes surviving retinal cells light-sensitive, so it works regardless of which gene caused the disease. The FDA accepted the application on September 9, 2026; Nanoscope has not disclosed an exact target action date. Its October 1, 2026 announcement of priority review in Japan said it expects potential approval in both Japan and the United States in the first half of 2027.
Who this decision matters to
Retinitis pigmentosa is a group of inherited retinal dystrophies causing progressive degeneration of the photoreceptor layer of the eye. Patients experience night blindness, progressive peripheral vision loss, and eventual central vision loss. Voretigene neparvovec (Luxturna) is FDA-approved for RPE65-associated retinal dystrophy, which includes some RP patients, though most RP subtypes still lack approved therapies.
Prevalence: Approximately 1 in 4,000 people worldwide. See our full Retinitis Pigmentosa page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Retinitis Pigmentosa treatment stands today
Read our full Retinitis Pigmentosa treatment summary
Gene therapy development is accelerating rapidly for retinitis pigmentosa, with multiple trials now actively recruiting qualified participants. Initial approaches target specific gene mutations known to cause RP, particularly X-linked and autosomal recessive forms where gene replacement has shown promise.
Genetic testing identifying your specific RP mutation is essential, as newer trials are mutation-specific and can only be accessed by patients carrying appropriate mutations. Some doctors suggest vitamin A supplements, but a 2020 Cochrane review of 4 trials found it uncertain whether vitamin A or DHA fish oil slows RP, so ask your retinal specialist before starting any supplement.
Work with a retinal specialist experienced in inherited dystrophies who can order comprehensive genetic testing, monitor disease progression precisely, and identify trial opportunities aligned specifically with your genetic subtype. Luxturna (voretigene neparvovec-rzyl), approved by the FDA in December 2017, can treat retinitis pigmentosa only when genetic testing confirms mutations in both copies of the RPE65 gene, a form the FDA's review calls RP type 20.
It does not treat retinitis pigmentosa caused by other genes.
The Retinitis Pigmentosa page has every treatment and trial →Meanwhile, 56 Retinitis Pigmentosa trials are recruiting
Whatever the FDA decides here, research on Retinitis Pigmentosa does not stop. A few currently enrolling studies, US sites first:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Retinitis Pigmentosa. Unsubscribe anytime.
Frequently asked questions
When will the FDA decide on Mogenry?
Nanoscope Therapeutics has not disclosed a decision date.
Who disclosed it: Nanoscope Therapeutics. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: Nanoscope press release
What is Mogenry being reviewed for?
Nanoscope Therapeutics submitted a BLA for Mogenry in Retinitis pigmentosa with severe vision loss.
What to know: One-time in-office injection that makes surviving retinal cells light-sensitive, so it works regardless of which gene caused the disease. The FDA accepted the application on September 9, 2026; Nanoscope has not disclosed an exact target action date. Its October 1, 2026 announcement of priority review in Japan said it expects potential approval in both Japan and the United States in the first half of 2027.
Is there already an FDA-approved treatment for Retinitis Pigmentosa?
Yes. Trial Friend's drug list includes 1 FDA-approved drug for Retinitis Pigmentosa.
Approved: Luxturna (voretigene neparvovec-rzyl).
Check: the Retinitis Pigmentosa page also searches FDA drug labels for approved treatments.
Can I get Mogenry before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 56 Retinitis Pigmentosa trials are recruiting now. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Nanoscope Therapeutics directly. Registered programs are listed on ClinicalTrials.gov.
How much will Mogenry cost?
Nanoscope Therapeutics has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Mogenry decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Nanoscope press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.